Dana-Farber Cancer Institute | Strategic Alliance Partners

February 10, 2015

The only therapeutic cancer vaccine ever to win approval from the FDA has repeatedly missed sales projections, plunging the company that developed it into bankruptcy proceedings.

December 17, 2014

November 26, 2014

The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.

November 05, 2014

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

November 04, 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

September 04, 2014

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

September 03, 2014

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

August 22, 2014

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.

August 13, 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

June 16, 2014

The concept of manipulating the immune system to treat cancer has experienced waxing and waning levels of enthusiasm over decades of clinical investigation.

March 13, 2014

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

March 06, 2014

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

March 03, 2014

A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

February 20, 2014

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

February 20, 2014

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer

February 12, 2014

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

February 05, 2014

Administering chemotherapy concurrently with androgen deprivation therapy (ADT), rather than saving cytotoxic treatment until after progression, improves overall survival for men with hormone-sensitive metastatic prostate cancer

January 27, 2014

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer.

January 07, 2014

Several new drugs have recently shown promise for the treatment of gastric cancer, including rilotumumab, ramucirumab, and anti-HER2 agents, according to a presentation at the 2013 Chemotherapy Foundation Symposium.

January 06, 2014

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.